Center of Excellence in Probiotics, Srinakharinwirot University, Bangkok 10110, Thailand.
Department of Microbiology, Faculty of Medicine, Srinakharinwirot University, Bangkok 10110, Thailand.
Nutrients. 2023 Jun 11;15(12):2710. doi: 10.3390/nu15122710.
Hypercholesterolemia is a significant risk factor for cardiovascular disease and metabolic disorders. Probiotics are the essential constituents of the gastrointestinal microbiota that provide health-promoting effects. Cholesterol-lowering activity is a specific property of probiotics, improving the cholesterol metabolism without adverse effects. Thus, the purpose of this study was to investigate the hypocholesterolemic effect of single and mixed cholesterol-lowering probiotic strains (including TF-7, TF-18, and TA-1) in high-cholesterol diet (HCD)-induced hypercholesterolemic rats. The results showed that the administration of single probiotics contributed to a reduction in the body weight gain, visceral organ indexes, hyperlipidemia, and hepatic steatosis and also an improvement in the gastrointestinal microbiota. Besides the effect of single cholesterol-lowering probiotics, three probiotics strains could also synergize their hypocholesterolemic effect when administered simultaneously. These findings indicate that three cholesterol-lowering probiotic strains are suitable for development as probiotic supplements to reduce the risk of diseases caused by cholesterol and exert health benefits with synergistic effect when administered simultaneously.
高胆固醇血症是心血管疾病和代谢紊乱的一个重要危险因素。益生菌是胃肠道微生物群的重要组成部分，具有促进健康的作用。降低胆固醇活性是益生菌的一种特殊特性，它可以改善胆固醇代谢，而没有不良反应。因此，本研究旨在探讨单一和混合降胆固醇益生菌菌株（包括 TF-7、TF-18 和 TA-1）在高胆固醇饮食（HCD）诱导的高胆固醇血症大鼠中的降胆固醇作用。结果表明，单一益生菌的给药有助于减轻体重增加、内脏器官指数、高脂血症和肝脂肪变性，并改善胃肠道微生物群。除了单一降胆固醇益生菌的作用外，三种益生菌菌株同时给药时也可以协同发挥降胆固醇作用。这些发现表明，三种降胆固醇益生菌菌株适合开发为益生菌补充剂，以降低胆固醇引起的疾病的风险，并在同时给药时发挥协同的健康益处。
